Julie Oestreich, Pharm.D., Ph.D.

Assistant Professor

Department of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
986045 Nebraska Medical Center
Omaha, NE 68198-6045
402-559-2916 (Office)
402-559-5673 (Fax)
joestreich@unmc.edu

Teaching Activities:

Dr. Oestreich teaches the pharmacogenomics elective.

Research Activities/Interests: 

Dr. Oestreich's lab is focused on studying the variability of platelet function and response to antiplatelet agents, particularly clopidogrel (Plavix) and other P2Y12 receptor antagonists. The goal of this research is to personalize patient therapy so that protection from adverse cardiovascular events is balanced with the lowest level of drug side effects, most notably bleeding.

Recent Publications:

1. Oestreich JH, Steinhubl SR, Ferraris SP, Akers WS. High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. Thrombo Haemost.2011 May;105(5):927-930.
2. Lanham K, Dunn S, Oestreich J, and Steinhubl S. Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmacogenomics and Personalized Medicine.2010;3:87-99.
3. Cavallari LH, Overholser BR, Anderson D, Boyce E, Buie L, Formea CM, Gallagher JC, Hayney MS, Oestreich J. ACCP Commentary: Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. Pharmacotherapy.2010;30(6):228e-235e.
4. Oestreich JH. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs.2010 Mar;11(3):340-348.
5. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol.2010;50(1):27-35.
6. Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist, for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs. 2009 Sep;10(9):988-996.
7. Oestreich JH, Holt J, Dunn SP, Smyth SS, Campbell CL, Charnigo R, Akers WS, Steinhubl SR. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis.2009 May;20(3):207-213.
8. Oestreich JH and Steinhubl SR. Cangrelor in percutaneous coronary intervention. Expert Rev Clin Pharmacol. 2009 Mar;2(2):137-145.
9. Oestreich JH, Smyth S, Campbell C. Platelet function analysis: at the edge of meaning. Thrombo Haemost. 2009 Feb;101(2):217-219.
10. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527-534.